Search
Metrizoic acid
go.drugbank.com/drugs/DB09346ApprovedA total of 10, 000 injections were administered to 2,028 patients undergoing angiocardiographic procedures over a three-year period. … Its approval has been discontinued by the FDA. One study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated.
DL-Methylephedrine
go.drugbank.com/drugs/DB11278ApprovedMethylephedrine is a sympathomimetic amine that appears in various over-the-counter cough and cold medications throughout the world [L2838], [L2839], [L2840].
Garadacimab
go.drugbank.com/drugs/DB15629Approved[L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan. … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.
Boric acid
go.drugbank.com/drugs/DB11326ApprovedInvestigationalBoric acid, also known as hydrogen borate, is a weak monobasic Lewis acid of boron with the chemical formula H3BO3. Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceu...
Mixtures: BENZAL EN POLVOVitamin D
go.drugbank.com/drugs/DB11094ApprovedInvestigationalNutraceuticalVet approvedVitamin D ultimately comprises a group of lipid-soluble secosteroids responsible for a variety of biological effects, some of which include increasing the intestinal absorption of calcium, magnesium, and phosphate. With reference to huma...
Mixtures: Multivit Et Fer Ampoules Et Comprimes, Vitamines Et MinerauxProducts: Vitamin D 1000 Iu TabletsZilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition
Sotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective. … [L34440] Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was
Verpasep caltespen
go.drugbank.com/drugs/DB04959InvestigationalE7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. … Verpasep caltespen is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from _Mycobacterium bovis_, and the human papilloma viral (HPV) protein E7.
Synonyms: BCG65-E7, HPV 16 E7/HSP65 vaccineVoxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalVosevi is approved for the treatment of adult patients with chronic HCV infection with genotype 1, 2, 3, 4, 5, or 6 infection [FDA Label]. … Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].